PMID- 29392373
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190128
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Linking)
VI  - 235
IP  - 4
DP  - 2018 Apr
TI  - Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute 
      schizophrenia: 12-week results from a prospective longitudinal study.
PG  - 1191-1198
LID - 10.1007/s00213-018-4835-6 [doi]
AB  - RATIONALE: It is generally accepted that impaired cognitive function is a core 
      feature of schizophrenia. There is evidence for the role of brain-derived 
      neurotrophic factor (BDNF) in cognitive function. Olanzapine was reported to 
      yield cognitive improvement in patients with schizophrenia. OBJECTIVES: In this 
      study, we performed a prospective, open-label, 12-week observation trial to 
      investigate whether peripheral BDNF may represent a potential biomarker for the 
      effect of cognitive improvement induced by olanzapine in patients with 
      schizophrenia. METHODS: In total, 95 patients with acute schizophrenia were 
      enrolled in the study. We also recruited 72 healthy individuals for a control 
      group. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate 
      symptom severity and treatment response. Cognitive function was evaluated using 
      the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). 
      Plasma BDNF levels were measured with an enzyme-linked immunosorbent assay. 
      RESULTS: Of the 95 patients consented into the study, 68 completed the 12-week 
      follow up. Our results showed that schizophrenia patients with acute exacerbation 
      had significantly poorer performance than that of the controls (Ps < 0.01). A 
      significantly decreased plasma level of BDNF in patients was observed compared 
      with the controls (F = 7.77, P = 0.006). A significant improvement in each PANSS 
      subscore and total score was observed when the patients completed this study 
      (Ps < 0.01). Additionally, 12-week olanzapine treatment exhibited significant 
      improvements in RBANS immediate memory, attention, and total scores (P = 0.018, 
      0.001, and 0.007, respectively). Along with the clinical improvement, plasma BDNF 
      levels after 12-week olanzapine monotherapy (4.67 +/- 1.74 ng/ml) were also 
      significantly increased compared with those at baseline (3.38 +/- 2.11 ng/ml) 
      (P < 0.01). Spearman's correlation analysis showed that the increase in plasma 
      levels of BDNF is significantly correlated with the change in the RBANS total 
      scores (r = 0.28, P = 0.02) but not with the change in the PANSS total scores 
      (r = - 0.18, P = 0.13). There is a significant correlation of BDNF increase with 
      the change of RBANS attention subscore (r = 0.27, P = 0.028). CONCLUSIONS: Our 
      findings suggest that olanzapine improves psychiatric symptoms and cognitive 
      dysfunction, particularly attention and immediate memory, in patients with acute 
      schizophrenia, in parallel with increased plasma BDNF levels. Plasma BDNF levels 
      may be a potential biomarker for cognitive recovery in acute schizophrenia.
FAU - Zhang, Yi
AU  - Zhang Y
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Fang, Xinyu
AU  - Fang X
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Fan, Weixing
AU  - Fan W
AD  - Department of Psychiatry, Jinhua Second Hospital, Jinhua, Zhejiang, China.
FAU - Tang, Wei
AU  - Tang W
AD  - Department of Psychiatry, Wenzhou Kangning Hospital, Wenzhou Medical University, 
      Wenzhou, Zhejiang, China.
FAU - Cai, Jun
AU  - Cai J
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Song, Lisheng
AU  - Song L
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China.
FAU - Zhang, Chen
AU  - Zhang C
AUID- ORCID: 0000-0003-4071-1627
AD  - Schizophrenia Program, Shanghai Mental Health Center, Shanghai Jiao Tong 
      University School of Medicine, Shanghai, China. zhangchen645@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180201
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - N7U69T4SZR (Olanzapine)
SB  - IM
MH  - Adult
MH  - Antipsychotic Agents/*therapeutic use
MH  - Biomarkers/blood
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - *Cognition/drug effects/physiology
MH  - *Cognition Disorders/blood/drug therapy
MH  - Female
MH  - Humans
MH  - Longitudinal Studies
MH  - Male
MH  - Memory, Short-Term
MH  - Middle Aged
MH  - Olanzapine/*therapeutic use
MH  - Prospective Studies
MH  - *Schizophrenia/blood/drug therapy
MH  - Young Adult
OTO - NOTNLM
OT  - Biomarker
OT  - Brain-derived neurotrophic factor
OT  - Cognitive function
OT  - Olanzapine
OT  - Schizophrenia
EDAT- 2018/02/03 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/02/03 06:00
PHST- 2017/08/11 00:00 [received]
PHST- 2018/01/14 00:00 [accepted]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/02/03 06:00 [entrez]
AID - 10.1007/s00213-018-4835-6 [pii]
AID - 10.1007/s00213-018-4835-6 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2018 Apr;235(4):1191-1198. doi: 
      10.1007/s00213-018-4835-6. Epub 2018 Feb 1.